Form 8-K - Current report:
SEC Accession No. 0001558370-25-008772
Filing Date
2025-06-20
Accepted
2025-06-20 16:05:41
Documents
17
Period of Report
2025-06-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sngx-20250620x8k.htm   iXBRL 8-K 77066
2 EX-10.1 sngx-20250620xex10d1.htm EX-10.1 141444
3 EX-10.2 sngx-20250620xex10d2.htm EX-10.2 107960
4 EX-10.3 sngx-20250620xex10d3.htm EX-10.3 136941
5 GRAPHIC sngx-20250620xex10d2001.jpg GRAPHIC 12388
  Complete submission text file 0001558370-25-008772.txt   658417

Data Files

Seq Description Document Type Size
6 EX-101.SCH sngx-20250620.xsd EX-101.SCH 4136
7 EX-101.DEF sngx-20250620_def.xml EX-101.DEF 3493
8 EX-101.LAB sngx-20250620_lab.xml EX-101.LAB 17256
9 EX-101.PRE sngx-20250620_pre.xml EX-101.PRE 10060
20 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20250620x8k_htm.xml XML 4842
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14778 | Film No.: 251061337
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)